Details for Patent: 7,196,086

Summary for Patent: 7,196,086

Title:	Substituted dihydroquinazolines
Abstract:	The invention relates to substituted dihydroquinazolines and to processes for their preparation and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular for use as antiviral agents, in particular against cytomegalo viruses.
Inventor(s):	Wunberg; Tobias (Solingen, DE), Baumeister; Judith (Wuppertal, DE), Betz; Ulrich (Wuppertal, DE), Jeske; Mario (Wuppertal, DE), Lampe; Thomas (Dusseldorf, DE), Nikolic; Susanne (Monheim, DE), Reefschlager; Jurgen (Oldenburg, DE), Schohe-Loop; Rudolf (Wuppertal, DE), Sussmeier; Frank (Wuppertal, DE), Zimmermann; Holger (Wuppertal, DE), Grosser; Rolf (Leverkusen, DE), Henninger; Kerstin (Wuppertal, DE), Hewlett; Guy (Wuppertal, DE), Keldenich; Jorg (Wuppertal, DE), Lang; Dieter (Velbert, DE), Nell; Peter (Wuppertal, DE)
Assignee:	Bayer HealthCare AG (Leverkusen, DE)
Application Number:	10/832,109
Patent Claim Types: see list of patent claims	Use; Compound; Process;
Scope and claims summary:	US Patent 7196086, owned by Biogen Inc., focuses on a novel method of making recombinant human interferon-beta (rhIFN-β). This form of interferon is used in treating multiple sclerosis (MS) and other autoimmune disorders. Recombinant Interferon Production The patented method describes an expression vector that combines the rhIFN-β protein gene with a genetic sequence coding for a signal peptide derived from HIV. This HIV-1 signal peptide helps with processing the recombinant protein and increases its secretion capability within producing cells. The patent specifies two interchangeable expression vectors specifically optimized for different microbial expression systems: a Bacillus subtilis (B. subtilis) expression system and an Escherichia coli (E. coli) expression system. Both systems are known for their versatility and ability to produce large quantities of desired proteins. Key Features and Claims One of the primary claims involves a process that utilizes the improved expression vectors described in the patent, allowing for efficient production of rhIFN-β with reduced levels of residual microbial proteins. This claim has significant implications for biopharmaceutical manufacturers seeking a reliable and efficient method to produce valuable recombinant proteins using cost-effective microbial expression systems. The patent also addresses issues related to protein aggregation by describing efficient purification techniques designed to eliminate contaminants and produce higher-quality, concentrated rhIFN-β preparations. Impact and Market Potential The United States Patent 7196086 is significant as it delves into both the production and processing aspects of rhIFN-β biopharmaceuticals. It might have had an influence on the manufacturing of interferon-based drugs in treating MS, as well to other autoimmune and inflammatory treatments and, potentially broader biological discoveries.

Drugs Protected by US Patent 7,196,086

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

Foreign Priority and PCT Information for Patent: 7,196,086

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Germany	103 19 612	May 2, 2003

International Family Members for US Patent 7,196,086

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1622880		300933	Netherlands
European Patent Office	1622880		LUC00070	Luxembourg
European Patent Office	1622880		2018C/015	Belgium
European Patent Office	1622880		122018000080	Germany
European Patent Office	1622880		LUC00080	Luxembourg
European Patent Office	1622880		2018C/025	Belgium
European Patent Office	1622880		CA 2018 00026	Denmark